3 not yet recruiting, 2 recruiting, 1 unknown. 4 Phase 2, 1 Phase 1, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Neuroendocrine Carcinomas (NEC): new trials by email Literature Review of Neuroendocrine Carcinomas (NEC) trials Research Report on Neuroendocrine Carcinomas (NEC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma ZG005 for Injection, Etoposide Injection, Cisplatin Injection - Neuroendocrine Carcinomas (NEC) | Phase 3 | Not yet recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 440 | 2026-10-01 | 2026-09-22 |
| Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma Sintilimab+Temozolomide+Surufatinib - Neuroendocrine Carcinomas (NEC) | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 32 | 2025-10-01 | 2025-09-04 |
| Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients Tarlatamab - Neuroendocrine Carcinomas (NEC), Neuroendocrine Carcinoma of Pancreas | Phase 2 | Recruiting | Inkeun Park | 60 | 2025-09-02 | 2026-04-13 |
| A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma Irinotecan Hydrochloride Liposome Injection, 5-FU, LV - Neuroendocrine Carcinomas (NEC) | Phase 4 | Not yet recruiting | Beijing GoBroad Hospital | 45 | 2025-06-20 | 2025-06-11 |
| A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel. - Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC) | Phase 1 / Phase 2 | Recruiting | Phanes Therapeutics | 203 | 2023-09-05 | 2026-07-15 |
| A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours 177Lu-Dotatate, Nivolumab - Neuroendocrine Tumours (NET), Neuroendocrine Carcinomas (NEC) | Phase 2 | Unknown | Fundación de investigación HM | 30 | 2020-06-29 | 2022-08-02 |
Carcinoma, Neuroendocrine (6) · Lung Neoplasms (1) · Neuroendocrine Tumors (1) · Small Cell Lung Carcinoma (1)
Adenocarcinoma (6) · Carcinoma (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Germ Cell and Embryonal (6) · Neoplasms, Glandular and Epithelial (6) · Neoplasms, Nerve Tissue (6) · Neuroectodermal Tumors (6) · Neuroendocrine Tumors (5) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Neoplasms by Site (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1)
Cisplatin (1) · DLL3 protein, human (1) · EC regimen (1) · Etoposide (1) · Fluorouracil (1) · Injections (1) · Irinotecan (1) · Nivolumab (1) · PM 01183 (1) · Paclitaxel (1) · Pharmaceutical Preparations (1) · Topotecan (1) · atezolizumab (1) · lutetium Lu 177 dotatate (1)
Beijing GoBroad Hospital (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Fundación de investigación HM (1) · Inkeun Park (1) · Phanes Therapeutics (1) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (1)
China (2) · South Korea (1) · Spain (1) · United States (1)
Antonio Cubillo, MD (1) · Inkeun Park, M.D, Ph D (1) · Yihebali Chi (1)